JasonDoiy
- Roche (RHHBY) unit Genentech has entered into a licensing agreement with Hanmi Pharmaceutical for the South Korean drugmaker’s novel obesity candidate, HM17321.
- Terms call for Hanmi to receive a $190M upfront payment. The deal value could reach $2.3B with milestone payments plus tiered
